On August 9 2023, BEAUTY HEALTH ($NASDAQ:SKIN) reported their earnings for the second quarter of fiscal year 2023 (ending June 30 2023). Total revenue was USD 117.5 million, a 13.5% increase from the same quarter of the previous year. Unfortunately, net income decreased 57.1% in comparison to the same quarter of the prior year, totaling USD 3.4 million.
On Wednesday, BEAUTY HEALTH released its quarterly financial report for the second quarter of the fiscal year 2023 ending June 30, 2023.
However, investors were not impressed with the results and the stock opened at $8.0 and closed at $7.1, representing a 5.4 percent drop from the prior closing price of $7.5. The drop in stock prices was mainly attributed to the company’s weak outlook for the coming quarter, with projected revenues falling short of analyst predictions. Despite this, BEAUTY HEALTH’s strong performance in the second quarter has given shareholders confidence that the company is still well-positioned to deliver profitable results in the near future. Overall, the second quarter report was generally positive for BEAUTY HEALTH and was a strong reminder that the company remains focused on delivering excellent results to its investors. It is now up to management to ensure that all future growth plans are implemented efficiently to ensure that BEAUTY HEALTH can continue to achieve record earnings for the foreseeable future. Live Quote…
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Beauty Health. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Beauty Health. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Beauty Health. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Beauty Health are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
Analysis – Beauty Health Intrinsic Value
At GoodWhale, we have conducted an analysis of the fundamentals of BEAUTY HEALTH Inc. Our proprietary Valuation Line has determined that the intrinsic value of BEAUTY HEALTH shares is approximately $22.9. Currently, BEAUTY HEALTH stocks are being traded at $7.1, meaning that the stock is undervalued by a whopping 69.0%. This presents an incredible opportunity for investors to purchase the stock at a discounted price. For those looking to create long-term value, investing in BEAUTY HEALTH stocks is a smart move. More…
Risk Rating Analysis
Star Chart Analysis
The company’s products are available in more than 30 countries and it has a strong presence in the United States, Europe, and Asia. The company’s products are sold through a network of distributors, retailers, and online retailers. The company has a strong focus on research and development and has a team of scientists that are constantly innovating new products. The company’s products are backed by a 100% satisfaction guarantee.
– Hims & Hers Health Inc ($NYSE:HIMS)
Hims & Hers Health Inc. is a digital healthcare company that offers direct-to-consumer telehealth and online pharmacy services. The company was founded in 2017 and is headquartered in San Francisco, California. As of 2022, the company had a market cap of 880.33M and a ROE of -15.86%. The company offers a range of services including primary care, sexual health, mental health, and more.
The company has a market cap of 47.13M as of 2022. The company’s ROE for the same period is 14.38%. The company is engaged in the business of manufacturing textile products.
– CI Medical Co Ltd ($TSE:3540)
Founded in 1971, CIC Medical is a leading provider of medical devices and services. The company’s products are used in a variety of medical applications, including surgery, diagnostics, and patient care. CIC Medical has a market cap of 51.4 billion as of 2022 and a return on equity of 15.93%. The company’s products are used in a variety of medical applications, including surgery, diagnostics, and patient care.
Beauty Health reported total revenue of USD 117.5 million for the fiscal year 2023 second quarter ending June 30, 2023, which represented a 13.5% increase from the same quarter of the previous year.
However, net income declined 57.1% year over year to USD 3.4 million. As a result, the company’s stock price dropped on the same day. Investors should look into this development and assess Beauty Health’s long-term growth potential before making any investment decision. While the company’s quarterly revenue was up, its net income declined significantly, raising questions about its ability to sustain profitable long-term growth.